Allergan Aesthetics Wins Canada Approval for Boey Neurotoxin
IRVINE, Calif., June 23, 2026 Allergan Aesthetics, an AbbVie company, announced that Health Canada has approved Boey® (trenibotulinumtoxinE) for...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
IRVINE, Calif., June 23, 2026 Allergan Aesthetics, an AbbVie company, announced that Health Canada has approved Boey® (trenibotulinumtoxinE) for...
IRVINE, Calif., June 16, 2026 Allergan Aesthetics, an AbbVie company, has received U.S. Food and Drug Administration (FDA) approval...
North Chicago, Illinois, USA – May 21, 2026 Allergan Aesthetics, an AbbVie company and global leader in medical aesthetics,...
